- All forms of epilepsy:
- Initially PO 0.5mg TDS
- May increase to 1mg/day after 3 days (up to 4mg/day in some patients)
- Panic disorders (with or without agoraphobia) resistant to antidepressant therapy
- Initially PO 0.25mg BD
- Increase by 0.25-0.5mg/day every 3 days
- Max: 4mg/day
- Essential tremor (Off-label):
- PO 0.5mg at bedtime
- Increase dose by 0.5mg every 3-4days
- Max 6mg/day
- REM sleep behavior disorder (Off-label):
- PO 0.25-2mg 30min prior to bedtime
- Max 4mg
- Restless legs syndrome, sleep terrors, sleepwalking:
- PO 0.5mg-2mg every night at bedtime
- Taken 30 min before bedtime
Tablet:
- 0.5mg
- 2mg
Taper dose gradually to discontinue
Long-acting benzodiazepine
It increases the presynaptic GABA inhibition and reduces the monosynaptic and polysynaptic reflexes. It suppresses muscle contractions by facilitating inhibitory GABA neurotransmission and other inhibitory transmitters
- Drowsiness
- Impaired coordination
- Dizziness
- Depression
- Fatigue
- Dysarthria
- Amnesia
- Asthenia
- Confusion
- Impaired concentration
- Disinhibition
- Libido changes
- Irritability
- Dystonia
- Diplopia
- Appetite changes
- Constipation
- Incontinence
- Urinary retention
- Hypotension
- Rash
- Elevated LFTs
- Hypersensitivity to class/components
- Severe hepatic impairment
- Acute narrow angle glaucoma
WARNING:
- Risk of addiction, abuse or misuse
- Concomitant benzodiazepine use with opioids may result in profound sedation, respiratory depression, coma and death
- Risk of dependence and withdrawal symptoms
- Amifampridine
- Bupropion
- Dalfampridine
- Metoclopramide
Drug Status
Availability | Prescription only |
Pregnancy | Category D |
Breastfeeding | Contraindicated |
Schedule | Controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Coclam | 2mg | Tablet | 30’s | Centaur Pharma | Sai Pharma |
Rivotril | 2mg | Tablet | 30’s | F. Hoffman-La Roche | Roche Kenya |
Rivotril | 0.5mg | Tablet | 50’s | F. Hoffman-La Roche | Roche Kenya |